Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia

PHASE3CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
HypoglycemiaDiabetes MellitusDrug-Specific Antibodies
Interventions
DRUG

Nasal Glucagon

3 mg nasal glucagon powder

Trial Locations (9)

12206

Albany Medical College Division of Community Endocrinology, Albany

55455

University of Minnesota, Minneapolis

02451-1136

New England Diabetes and Endocrinology Center (NEDEC), Waltham

R3C 0N2

Winnipeg Clinic, Winnipeg

K7A 4W8

Diabetes Clinic, Smiths Falls

H2W 1R7

IRCM, Montreal

G1V 4G2

Centre Hospitalier de l'Université de Québec, Québec

J1G 5K2

Centre de recherche d'endocrinologie Godin & St-Pierre, Sherbrooke

H3Z 1E5

Applied Medical Informatics Research, Westmount

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Locemia Solutions ULC

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT02171130 - Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia | Biotech Hunter | Biotech Hunter